Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 604

Sort by

Sort Order Select

Journal Articles

The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma

Blood (2025) 146 (11): 1286–1299.

https://doi.org/10.1182/blood.2024026340

Published: 2025

Includes: Supplemental data

Journal Articles

CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs

Blood (2025) 146 (7): 847–860.

https://doi.org/10.1182/blood.2025028746

Published: 2025

Includes: Supplemental data

Journal Articles

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

Joshua Rivera, Qi Yan, Saeed Daneshmandi, Romain Lannes, Eriko Katsuta, Jee Eun Choi, Prashant K. Singh, Ahmed Belal, Ronald Alberico, Ian Lund, Magan Schaefer, Hamza Hassan, Sarah Parker, Kenneth C. Anderson, Nikhil C. Munshi, Mehmet K. Samur, Philip L. McCarthy, Jens Hillengass, Hemn Mohammadpour

Blood blood.2025028963.

https://doi.org/10.1182/blood.2025028963

Published: 2025

Includes: Supplemental data

Journal Articles

Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma

Chandraditya Chakraborty, Srikanth Talluri, Moritz Binder, Eugenio Morelli, Jessica Encinas Mayoral, Sanika Derebail, Anil Aktas Samur, Charles Epstein, Kenneth C. Anderson, Masood Shammas, Mehmet K. Samur, Mariateresa Fulciniti, Nikhil C. Munshi

Blood (2025) 146 (1): 104–114.

https://doi.org/10.1182/blood.2024026588

Published: 2025

Includes: Supplemental data

Journal Articles

Development of hyperdiploidy starts at an early age and takes a decade to complete

Mehmet K. Samur, Anil Aktas Samur, Parth Shah, Joseph S. Park, Mariateresa Fulciniti, Masood Shammas, Jill Corre, Kenneth C. Anderson, Giovanni Parmigiani, Hervé Avet-Loiseau, Nikhil C. Munshi

Blood (2025) 145 (5): 520–525.

https://doi.org/10.1182/blood.2024025250

Published: 2025

Includes: Supplemental data

Journal Articles

Deciphering Drivers of Functional and Phenotypic Changes through Genome-Wide Screen (DRIVE-Genome) to Identify Genes Inducing Genomic Instability in Myeloma

Srikanth Talluri, Leutz Buon, Jiangning Zhao, Daniel Meglino, Chandraditya Chakraborty, Chengcheng Liao, Mehmet K. Samur, David E. Root, Masood A. Shammas, Nikhil C. Munshi

Blood (2024) 144 (Supplement 1): 4133.

https://doi.org/10.1182/blood-2024-210496

Published: 2024

Journal Articles

Isoform-Level Long Noncoding RNA Dependencies in Multiple Myeloma

Eugenio Morelli, Anil Aktas-Samur, Domenico Maisano, Claire Gao, Vanessa Favasuli, Dimitrios Papaioannou, Na Liu, Marcello Turi, Pietro Folino, Laure Vreux, Michela Cumerlato, Liang Cheng, Iannis Aifantis, Mariateresa Fulciniti, Kenneth C. Anderson, Annamaria Gulla, Mehmet K. Samur, Nikhil C. Munshi

Blood (2024) 144 (Supplement 1): 4130.

https://doi.org/10.1182/blood-2024-209546

Published: 2024

Journal Articles

Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment

Blood (2024) 144 (Supplement 1): 3289.

https://doi.org/10.1182/blood-2024-211352

Published: 2024

Journal Articles

Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström's Macroglobulinemia and Represent Novel Therapeutic Targets.

Blood (2024) 144 (Supplement 1): 2972.

https://doi.org/10.1182/blood-2024-211759

Published: 2024

Journal Articles

A Focused High Throughput Functional Screen Identifies Novel Targets for aggressive B-Cell Lymphoma

Chengcheng Liao, Sha He, Jie Sun, Qing Ke, Chao Rong, Baoping Guo, Xiaohong Tan, Srikanth Talluri, Masood A. Shammas, Nikhil C. Munshi, Hong Cen

Blood (2024) 144 (Supplement 1): 5758.

https://doi.org/10.1182/blood-2024-209515

Published: 2024

Journal Articles

Development of Novel Peripheral Blood Count-Based Prognostic Index for Multiple Myeloma

Grace M. Ferri, Cenk Yildirim, Joseph Park, Nhan V. Do, Mary T. Brophy, Nikhil C. Munshi, Nathanael R. Fillmore, Camille V. Edwards

Blood (2024) 144 (Supplement 1): 6981.

https://doi.org/10.1182/blood-2024-206313

Published: 2024

Journal Articles

The Mitochondrial Protease Clpp Is a Metabolic Vulnerability and an Immunogenic Trigger Against Multiple Myeloma

Tommaso Perini, Paola Zordan, Rossella Del Pizzo, Massimo Resnati, Ugo Orfanelli, Davide Stefanoni, Laura Cassina, Laura Oliva, Mehmet K. Samur, Lisa Viviani, Maria Materozzi, Matteo Trudu, Alessandra Boletta, Enrico Milan, Fabio Ciceri, Nikhil C. Munshi, Matteo Bellone, Simone Cenci

Blood (2024) 144 (Supplement 1): 765.

https://doi.org/10.1182/blood-2024-201364

Published: 2024

Journal Articles

PKMYT1 Kinase Is an Actionable Synthetically Lethal Target for Del17p Myeloma

Anais Schavgoulidze, Mariateresa Fulciniti, Giulia Giorgetti, Sabrina Maheo, Shuhui Deng, Vanessa Favasuli, Srikanth Talluri, Masood A. Shammas, Luka Pavageau, Anil Aktas-Samur, Mehmet K. Samur, Herve Avet-Loiseau, Jill Corre, Nikhil C. Munshi

Blood (2024) 144 (Supplement 1): 764.

https://doi.org/10.1182/blood-2024-199692

Published: 2024

Journal Articles

Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA- or GPRC5D-Targeted Immunotherapies

Rosa Toenges, Jean-Baptiste Alberge, Francesco Corrado, Nayda Bidikian, David M. Cordas Dos Santos, Ankit K. Dutta, Elizabeth D. Lightbody, Romanos Sklavenitis Pistofidis, Adam S. Sperling, Kenneth C. Anderson, Shonali Midha, Yuxin Liu, Jacob P. Laubach, Eric L. Smith, Nikhil C. Munshi, Omar Nadeem, Irene Ghobrial, Gad Getz

Blood (2024) 144 (Supplement 1): 492.

https://doi.org/10.1182/blood-2024-204132

Published: 2024

Journal Articles

Risk Factors for Suboptimal Treatment in Patients with Newly Diagnosed Multiple Myeloma across US Healthcare Systems

Geethika Bodanapu, June Corrigan, John Culnan, Maya Srinivasan, Mehar Hora, Alexander Lazzaro, Cenk Yildirim, Danne Elbers, Deborah Lang, Nhan V. Do, Mary T. Brophy, Britney Bell, Raphael E. Szalat, Nikhil C. Munshi, Nathanael R. Fillmore, Camille V. Edwards

Blood (2024) 144 (Supplement 1): 3341.

https://doi.org/10.1182/blood-2024-198815

Published: 2024

Journal Articles

Evaluation of Socioeconomic Barriers Impacting Patients with Newly Diagnosed Multiple Myeloma

Maya D. Srinivasan, John Culnan, Mehar Hora, Alexander Lazzaro, Britney Bell, Geethika Bodanapu, Cenk Yildirim, June Corrigan, Nhan V. Do, Mary T. Brophy, Nikhil C. Munshi, Raphael E. Szalat, Nathanael R. Fillmore, Camille V. Edwards

Blood (2024) 144 (Supplement 1): 5169.

https://doi.org/10.1182/blood-2024-211465

Published: 2024

Journal Articles

A TCR-like CAR T Cell Therapy for the Treatment of MZB1 Positive Multiple Myeloma and Other B-Cell Malignancies

Elena Maroto Martin, Yingjie Zhao, Sara Mangesh Kolhatkar, Roberto Garcia-Vicente, Mubin Tarannum, Mehmet K. Samur, Mariateresa Fulciniti, Rizwan Romee, Jianzhu Chen, Nikhil C. Munshi

Blood (2024) 144 (Supplement 1): 4800.

https://doi.org/10.1182/blood-2024-208607

Published: 2024

Journal Articles

Prolonged Persistence and Functional Activity of Anti-BCMA CAR-T Durcabtagene Autoleucel (PHE885) Manufactured Using the T-Charge™ Platform

Blood (2024) 144 (Supplement 1): 149.

https://doi.org/10.1182/blood-2024-199890

Published: 2024

Journal Articles

Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma

Nayda Bidikian, Francesco Corrado, Romanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Rosa Toenges, Jean-Baptiste Alberge, Michelle P. Aranha, Ting Wu, Michael Timonian, Shonali Midha, Elizabeth K. O'Donnell, Yuxin Liu, Sophie Magidson, Ashlee Strutevant, Kenneth C. Anderson, Nikhil C. Munshi, Omar Nadeem, Gad Getz, Irene Ghobrial

Blood (2024) 144 (Supplement 1): 488.

https://doi.org/10.1182/blood-2024-207299

Published: 2024

Journal Articles

Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Bruno Paiva, Irene Manrique, Ethan G. Thompson, Timothy B. Campbell, Camila Guerrero, Nathan Martin, Larry D Anderson, Jr., Jesus G Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, Philippe Moreau, Jesús F. San-Miguel, Nikhil C. Munshi, Shari Kaiser

Blood (2024) 144 (Supplement 1): 900.

https://doi.org/10.1182/blood-2024-203007

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma

CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma

Development of hyperdiploidy starts at an early age and takes a decade to complete

Deciphering Drivers of Functional and Phenotypic Changes through Genome-Wide Screen (DRIVE-Genome) to Identify Genes Inducing Genomic Instability in Myeloma

Isoform-Level Long Noncoding RNA Dependencies in Multiple Myeloma

Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment

Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström's Macroglobulinemia and Represent Novel Therapeutic Targets.

A Focused High Throughput Functional Screen Identifies Novel Targets for aggressive B-Cell Lymphoma

Development of Novel Peripheral Blood Count-Based Prognostic Index for Multiple Myeloma

The Mitochondrial Protease Clpp Is a Metabolic Vulnerability and an Immunogenic Trigger Against Multiple Myeloma

PKMYT1 Kinase Is an Actionable Synthetically Lethal Target for Del17p Myeloma

Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA- or GPRC5D-Targeted Immunotherapies

Risk Factors for Suboptimal Treatment in Patients with Newly Diagnosed Multiple Myeloma across US Healthcare Systems

Evaluation of Socioeconomic Barriers Impacting Patients with Newly Diagnosed Multiple Myeloma

A TCR-like CAR T Cell Therapy for the Treatment of MZB1 Positive Multiple Myeloma and Other B-Cell Malignancies

Prolonged Persistence and Functional Activity of Anti-BCMA CAR-T Durcabtagene Autoleucel (PHE885) Manufactured Using the T-Charge™ Platform

Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma

Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only